Articles

In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor

GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, UK;
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, UK;
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, UK;
Drug Discovery Unit, Cancer Research UK Manchester Institute, Univ of Manchester & MediTech Media,UK;
Cancer Research UK Manchester Institute, Univ of Manchester & Charles River Laboratories, Essex, UK;
Cancer Research UK Manchester Institute, Univ of Manchester & Framingham Consulting Limited, UK;
GlaxoSmithKline, Collegeville, PA & Prelude Therapeutics, Newark, DE, USA
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, UK;
GlaxoSmithKline, Collegeville, Pennsylvania, USA;
Haematologica Early view Jun 25, 2020 https://doi.org/10.3324/haematol.2020.248658